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PURPOSE. To investigate the clinical features of subjects with
glaucoma with the E50K mutation in the optineurin (OPTN)
gene and to compare the onset, severity, and clinical course of
these patients with a control group of subjects with glaucoma
without this mutation.
METHODS. The phenotype of well-characterized subjects from
Moorfields Eye Hospital, London, who had been identified as
carrying the OPTN E50K mutation was examined. A wide range
of structural, psychophysical, and demographic factors were
then compared with those in a control group of subjects with
glaucoma without this mutation.
RESULTS. Eleven subjects with glaucoma with the E50K muta-
tion (nine in two families and two sporadic cases) were stud-
ied. All 11 subjects had normal tension glaucoma (NTG), with
presenting and highest IOP of 15.3  3.0 and 16.5  2.5 mm
Hg (SD) on diurnal testing. Compared with 87 NTG control
subjects who did not have this mutation, subjects with E50K
presented at a younger age (40.8  15 years, P  0.0001) and
had more advanced optic disc cupping (mean cup-disc ratio 
SD 0.86  0.1, P  0.001) and smaller neuroretinal rim area
(SD; 0.5  0.28 mm2, P  0.001) at diagnosis. The rate of
filtration surgery performed for progressive visual field loss in
those with and without the E50K mutation was 72.7% and
25.3%, respectively (P  0.003), and all subjects with E50K
were found to have progressing visual fields. In addition, seven
E50K mutation-carrying individuals in two families (age range,
23–58 years) presented with normal optic discs and visual
fields and, as yet, no signs of glaucoma.
CONCLUSIONS. In this study, subjects with glaucoma who had
the OPTN E50K mutation were found to have NTG that ap-
peared to be more severe than that in a control group of
subjects with NTG without this mutation. The findings empha-
size the importance of early detection and treatment of glau-
coma in such individuals, to minimize visual loss. (Invest Oph-
thalmol Vis Sci. 2005;46:2816–2822) DOI:10.1167/iovs.04-
1133
Glaucoma, the leading cause of irreversible blindnessworldwide affecting approximately 70 million people,1,2
is typified by progressive loss of optic nerve axons and visual
field damage. Because it is insidious, the disease is frequently
detected only when patients have advanced irreversible visual
impairment. Primary open-angle glaucoma (POAG) is the most
common form of glaucoma worldwide and accounts for most
of the glaucoma in white and Afro-Caribbean populations.3–6
The prevalence of POAG increases with age, and intraocular
pressure (IOP) is a major risk factor for glaucomatous optic
nerve damage.4,7
Glaucoma is thought to have a substantial heritable basis, as
illustrated by the numerous linked loci, number of genes iden-
tified to date, and a significant proportion of patients with
glaucoma who show a positive family history.8–11 In 1997,
myocilin (MYOC, MIM 601652; Mendelian Inheritance in Man;
National Center for Biotechnology Information, Bethesda, MD)
mapping to the 1q24.3 region,12 was the first gene found to be
mutated in patients with POAG.13 Subsequent studies found
that MYOC mutations account for fewer than 5% of all cases of
juvenile- and adult-onset POAG.13–17 Recently, Rezaie et al.18
identified a second POAG gene, optineurin (OPTN; MIM
602432) from within the GLC1E interval on 10p13,19 and
showed that variations in this gene predominantly result in
normal tension glaucoma (NTG), a major subtype of POAG, in
which IOPs are constantly within the statistically normal pop-
ulation range. The most common OPTN mutation, Glu503Lys
(E50K) was found to be a significant cause of glaucoma iden-
tified in 13.5% of families studied.18,20
Knowledge of the clinical behavior of specific mutations is
helpful in disease management by providing patients and cli-
nicians with useful information regarding the course and prog-
nosis of the disease. This is illustrated in POAG with the finding
that the Ile477Asn and Tyr437His mutations in the MYOC gene
are associated with a more severe form of glaucoma with an
early age of onset, high IOP, and resistance to medical treat-
ment,14,21 whereas the Gln368STOP MYOC mutation causes a
much less virulent form of disease.14,22–24 The purpose of this
study was to investigate the clinical features of subjects with
the OPTN E50K mutation to determine whether this mutation
imparts a characteristic phenotype in patients with glaucoma.
The onset, severity, and clinical course of these patients were
then compared with those in a group of patients with glau-
coma who did not have the OPTN E50K mutation.
METHODS
The clinical features of all patients attending glaucoma clinics at Moor-
fields Eye Hospital, London, who had been identified as having the
E50K mutation in the OPTN gene, were examined. The study had the
approval of the Moorfields Eye Hospital ethics committee and was
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performed in accordance with the Helsinki Declaration. These subjects
had been included in four separate genetic studies, the methodologies
of which have been described elsewhere18–20,25 and are summarized as
follows. In one study, 54 POAG families were selected from a national
database of families with glaucoma, because at least one member of
each family had NTG.18 Seven families were found to have the E50K
mutation, of which two families were examined at this hospital, as they
lived in the London area. In another study, the possibility of the E50K
mutation as a founder effect in the same seven families was excluded.20
In a more recent study, 315 unrelated persons, cases of sporadic
POAG, were screened for the OPTN E50K mutation only (but not the
entire OPTN gene), of which 2 subjects were found to have the
mutation.25
POAG was defined according to the following diagnostic criteria:
the presence of typical glaucomatous optic neuropathy with compat-
ible visual field loss; open drainage angles on gonioscopy; and the
absence of a secondary cause for glaucomatous optic neuropathy, such
as previous trauma, a period of steroid administration, or uveitis.
Patients with POAG who had mean IOP without treatment that was
consistently 21 mm Hg on diurnal testing were classified as having
NTG.
The following data were collected: demographic characteristics
including gender and age at diagnosis of glaucoma; family history of
glaucoma; history of ischemic risk factors such as hypertension, dia-
betes mellitus, ischemic heart disease, and smoking; history of vaso-
spasm such as migraine and cold hands and feet; the presenting and
highest recorded diurnal IOP as measured by applanation tonometry;
cup-disc (CD) ratio at presentation; and interocular symmetry of glau-
coma. The treatment administered and history of filtration surgery was
also recorded.
Subjects underwent static automated white-on-white threshold pe-
rimetry (program 24-2, Humphrey perimeter, model 640; Carl Zeiss
Meditec, Dublin, CA). The first two visual field tests for all subjects
were discarded from the analyses to allow for learning effects, and the
subsequent first reliable visual field was used as the baseline. The
global indices, mean deviation (MD), and corrected pattern SD (CPSD)
of the baseline visual fields were analyzed. The visual fields of a
subgroup of subjects who had at least 5 years of follow-up were also
analyzed on computer for progression by point-wise linear regression
(Progressor for Windows software; OBF Labs. Ltd., Malmesbury, UK).26
Progression was defined as the presence of a significant regression
slope (P  0.01) showing 1 dB per year or more of sensitivity loss at
the same test location with the addition of two of three successive field
tests to the series. The mean number of progressing locations, the
mean slope for the progressing locations, and the mean slope of the
whole visual field per year were evaluated.
The Heidelberg retina tomograph (HRT; Heidelberg Engineering,
Heidelberg, Germany) was used to image the optic disc, and the
baseline optic disc parameters were analyzed. The mean topography of
three images was generated in the 10°  10° frame, and the disc edge
was delineated on the mean image by a single trained observer. Images
with significant movement artifact were rejected. Global and segmen-
tal disc and cup areas were analyzed directly by means of the HRT
software (ver. 2.01b) using the standard reference plane.
Control Group
A control group of 87 NTG subjects who did not carry the OPTN E50K
mutation25 was selected for comparison, using identical study meth-
odology and data collection. Only those who had undergone repeated
automated perimetry (with at least 5 years of follow-up), as well as
imaging of the optic disc with the HRT, were eligible for selection as
control subjects.
Statistical Analysis
Only one eye of each patient was analyzed. This was randomly selected
in bilateral cases, and the affected eye was selected in unilateral cases.
FIGURE 1. Complete pedigree structures for two families with the OPTN E50K mutation. (A) Pedigree 1, the original GLC1E-linked family. The six
affected subjects included in this study are shown within a circle. (B) Pedigree 2. Phenotype information is included on the pedigrees: POAG with
E50K mutation (filled symbols), asymptomatic mutation carriers (dotted symbols), normal individuals without mutation (unfilled symbols).
Diagonal line through a symbol identifies the deceased individuals. Individuals’ pedigree number and year of birth (only for the seven
asymptomatic mutation carriers included in this study) are shown.
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Statistical analysis was performed on computer (Statistical Package for
Social Sciences, ver. 9.0; SPSS Inc., Chicago, IL). Parametric and non-
parametric tests of significance were performed when appropriate.
Comparisons between groups were performed with Mann-Whitney
tests for continuous variables that were not normally distributed. The
2 analysis was used for comparison of proportions. Statistical signifi-
cance was assumed at P  0.05, and significant statistical associations
were corrected by the Bonferroni test for multiple comparisons (20
comparisons made).
RESULTS
Eleven white subjects with glaucoma treated at Moorfields Eye
Hospital had been found to have the OPTN E50K mutation.18,25
Six of the subjects were from one family (circled individuals in
pedigree 1; Fig. 1A), which was actually part of an original
GLC1E pedigree (consisting of 15 living affected individuals)
described in three previous publications.18–20 Although stud-
ies had shown that all 15 living affected subjects and 6 asymp-
tomatic members of this family carried the OPTN E50K muta-
tion,18,20 only those examined at Moorfields Eye Hospital were
included in the study, and the clinical features of the other
subjects from this pedigree were not included. Another three
subjects with glaucoma were from a second family (pedigree 2;
Fig. 1B).18,20 The glaucoma phenotype in both pedigrees seg-
regated as an autosomal dominant condition (Fig. 1), and every
glaucoma-affected person carried the E50K mutation.18,20 Two
unrelated sporadic NTG cases were also identified with this
mutation in a separate study.25
Table 1 lists the age, sex, age at diagnosis, laterality, pre-
senting CD ratio, presenting MD and CPSD, and surgical treat-
ment of the 11 patients with the OPTN E50K mutation. All 11
subjects were classified as having NTG, with presentation of
highest IOP (on diurnal testing) of 15.3  3.0 mm Hg (mean 
SD; range, 12–20) and 16.5  2.5 mm Hg (range, 12–21 Hg),
respectively. One subject (individual 2 in pedigree 1; Fig. 1A)
had one previous IOP reading of 23 mm Hg (measured by an
optician), though IOP was consistently less than 21 mm Hg
when measured subsequently in the hospital during diurnal
testing. The mean (SD) corneal thickness was 543 10.6 m
(range, 533–558). The mean age at diagnosis was 40.8  15
years (range, 24–59) with only 2 of 11 subjects diagnosed
when older than 50 years. All but one subject had bilateral
disease. This 56-year-old (individual 1 in pedigree 1; Fig. 1A)
had a cup-disc ratio of 0.8 and visual field defects in one eye,
but the other eye had a cup-disc ratio of 0.6 with normal visual
fields and HRT tests. The glaucomatous eye had a few signs of
pigment dispersion syndrome, but IOP was consistently within
the normal range.
Most of the subjects with NTG presented with relatively
advanced disease: the mean CD ratio at the time of diagnosis
was 0.86  0.1, and all but one subject had a CD ratio 0.8.
Visual field status was also severe at the time of diagnosis: 8 of
11 subjects had presenting MD  15.0 dB, and 7 of 11
subjects had presenting CPSD 10.0 dB. One subject was
already blind at the time of diagnosis, with bilateral central
visual fields of 20°. Eight of the 11 subjects with glaucoma
had undergone filtration surgery for progressive visual field
loss.
Comparison with the Control Group
The clinical features of the 11 NTG subjects with the OPTN
E50K mutation were compared with those of 87 NTG subjects
without this mutation. There was no significant difference in
the two groups with respect to gender, history of ischemic risk
factors or vasospasm, or laterality of glaucoma (Table 2). Pa-
tients with NTG who had the OPTN E50K mutation, however, TA
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were younger when first diagnosed (P  0.0001; Bonferroni-
adjusted P  0.002). The comparisons of IOP, CD ratio, visual
field global indices, MD and CPSD, and rate of surgery in the
two groups are summarized in Table 3. Patients with NTG who
had the OPTN E50K mutation had lower mean peak IOP on
diurnal testing (P  0.01; Bonferroni-adjusted P  0.2), and
lower mean presenting IOP, which approached significance
(P  0.06). These patients also had worse initial cup-disc ratio
(P  0.001; Bonferroni-adjusted P  0.02) and higher mean
presenting MD of initial visual fields (P  0.006; Bonferroni-
adjusted P  0.12). However, there was no significant differ-
ence in the initial CPSD. Eight (72.7%) patients with the OPTN
E50K mutation underwent filtration surgery for progression of
visual field loss, compared with 22 (25.3%) of 87 patients
without this mutation (P  0.003; Bonferroni-adjusted P 
0.06).
The presenting optic disc parameters (as measured by HRT)
are summarized in Table 4. There was no difference in the
mean optic disc area. However, optic discs of nine patients
with the OPTN E50K mutation (HRT scans of two subjects
were not interpretable due to poor quality of images) had
smaller mean neuroretinal rim areas (global, nasal, and tempo-
ral) than did the control subjects. The difference was more
marked in the nasal neuroretinal rim, for both superior and
inferior nasal rim areas. Comparing the visual fields of the
subgroup of subjects who had at least 5 years of follow-up, all
8 (100%) subjects with the OPTN E50K mutation were found to
have progressing locations, compared with 71 (81.6%) of 87 of
those without this mutation (P  0.34). There was no differ-
ence in the mean number of progressing locations per subject,
the mean slope of the progressing locations, or the mean slope
for the whole visual field (Table 5).
Asymptomatic Gene Carriers
In addition, in an earlier study, we reported seven E50K mu-
tation-carrying individuals from the two pedigrees (Fig. 1A, 1B)
who had normal optic discs and visual fields and as yet showed
no signs of glaucoma.18,20 Their ages ranged from 23 to 58
years (their years of birth are shown under subject symbols in
Fig. 1).
DISCUSSION
In this study, all subjects with glaucoma with the E50K muta-
tion in the OPTN gene were found to have NTG, with IOP
usually below 16 mm Hg (mean, 15.3 mm Hg). The highest
measured IOP on diurnal testing was found to be significantly
lower (mean, 16.5 mm Hg) than in a control group of other
NTG subjects without the mutation. The corneal thickness in
these individuals was in the normal range (533–558 m),
which suggests that IOP was not influenced by an abnormal
corneal thickness and contrasts with the finding of thinner
corneas in other NTG subjects.27–30 Unfortunately, corneal
thickness data were not available in the control group of NTG
subjects.
NTG has been reported to be more common in patients
identified through population screening than among patients
with glaucoma diagnosed in routine clinical practice.31 As
patients are usually asymptomatic and as the condition is dif-
ficult to diagnose, patients with NTG often have marked irre-
TABLE 3. Comparison of Clinical Features between Patients with NTG, with and without the OPTN
E50K Mutation
Group 1
(n  11)
Group 2
(n  87) P Corrected P
Mean presenting IOP (mm Hg) 15.3  3.0 17.0  2.7 0.06
Mean highest diurnal IOP (mm Hg) 16.5  2.5 18.8  2.6 0.01 0.2
Mean presenting cup-disc ratio 0.86  0.1 0.76  0.1 0.001 0.02
Mean presenting MD (dB) 16.0  9.5 7.8  6.8 0.006 0.12
Mean presenting CPSD (dB) 9.7  4.7 8.1  4.4 0.25
Number who underwent filtration surgery
for visual field progression, n (%) 8 (72.7) 22 (25.3) 0.003 0.06
TABLE 2. Comparison between Patients with NTG, with and without the OPTN E50K Mutation
Group 1
(n  11)
Group 2
(n  87) P Corrected P
Sex  0.99
Male 3 (27.3) 23 (26.4)
Female 8 (72.7) 64 (73.6)
Age at diagnosis (y)  0.0001 0.0003
60 years 11 (100) 33 (37.9)
60 years 0 (0) 54 (62.1)
Mean age at diagnosis (y) 40.8  11.0 61.7  10.1 0.0001 0.002
Ischemic risk factors 0.74
Positive 3 (27.3) 33 (37.9)
Negative 8 (72.7) 54 (62.1)
Vasospasm 0.24
Positive 4 (36.4) 17 (19.5)
Negative 7 (63.6) 70 (80.5)
Laterality 0.68
Bilateral 10 (90.9) 70 (80.5)
Unilateral 1 (9.1) 17 (19.5)
Data, showing demographic features, are n, with the percentage of the total group in parentheses,
unless noted otherwise.
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versible visual damage at the time of diagnosis. Subjects with
the E50K mutation in this study were found to have advanced
optic disc cupping, neuroretinal rim thinning, and visual field
damage when first examined. The degree of glaucomatous
damage at the time of diagnosis exceeded that of other subjects
with NTG without the mutation, despite the fact that some of
the subjects in the two pedigrees had been screened for glau-
coma at a younger age, because they had a positive family
history. This was noteworthy, as one would expect subjects
diagnosed earlier because of an ascertainment bias to have less
severe optic nerve damage. The findings emphasize the impor-
tance of early detection of glaucoma in individuals at risk, such
as those with a family member affected by this mutation.
The glaucomatous disease process caused by the E50K
mutation is also characterized by a progressive course (Fig. 2),
with visual field progression detected in all subjects (over 5
years), as opposed to 81% of control subjects with and 77% in
a previously reported series of subjects with NTG.32 Filtration
surgery for visual field progression was performed in 72% of
NTG cases with E50K mutation compared with only 25% in
those without this mutation. All patients were under the care
of the Moorfields Eye Hospital NTG clinic under the supervi-
sion of a senior ophthalmologist (RAH), and the indication for
surgery was primarily for progressive visual field loss. Fol-
low-up was at least 5 years in all cases. The therapeutic impli-
cations of this finding are that close monitoring and earlier
intervention may be necessary in these subjects, to minimize
visual loss. Treatment in such cases could involve lowering of
IOP by 20% or more, as this has been found to alter the course
of visual field progression favorably in some patients with
NTG.33–39 However, with starting IOPs in the 12- to 18-mm Hg
range, this may be difficult to achieve except by means of
filtration surgery, possibly augmented by antiproliferative
drugs.39
Although there is likely to be some bias toward earlier
diagnosis because of a positive family history, the E50K muta-
tion seems to predispose individuals to an early age of onset in
young adulthood (mean age at diagnosis, 40 years), which is
approximately two decades earlier than most persons with
NTG, and all subjects (including the two with sporadic cases)
were diagnosed before the age of 60. There was, however,
some variation in the age of onset of disease. There were two
individuals with the mutation who were diagnosed in their 20s,
whereas others were diagnosed in their 50s. We found seven
E50K mutation-carrying individuals (age range, 23–58 years)
who had normal optic discs and visual fields and as yet showed
no signs of glaucoma.18,20 It was not possible to ascertain the
penetrance of E50K, as most asymptomatic carriers were
young, and in them, glaucoma may develop by the time they
reach the ages of the affected individuals in the study.
The mechanism by which the E50K mutation causes disease
is unknown. Vittitow and Borras40 studied the effect of glau-
comatous insults on the expression of OPTN in human eyes
maintained in organ culture. Sustained elevated IOP, TNF-
exposure, and prolonged dexamethasone treatment all signifi-
cantly upregulated OPTN expression, suggesting a protective
role of OPTN in the trabecular meshwork.40 The recurrent
E50K mutation is located within a putative bZIP motif, con-
served in the mouse, bovine, and macaque genomes, and it was
hypothesized that visual loss and optic neuropathy may be the
result of a dominant negative effect.18,20 It remains to be seen
if there are other molecular mechanisms or factors mediating
NTG that interact with this gene.
Although all subjects with glaucoma with the E50K muta-
tion in this study were found to have NTG and a predominant
NTG phenotype associated with E50K has also been docu-
mented,19–20 affected individuals with high IOPs have been
reported. For example, three members of the extended family
of pedigree 1 were observed to have IOPs of 23 to 25 mm
Hg,19,20 and 18% of individuals among the seven families iden-
tified with the E50K mutation had a high IOP.18,20 Although
such high IOPs may reflect diurnal fluctuations,41,42 it is pos-
sible that there is some phenotypic variability in IOP. Other
mutations in OPTN have also been reported in cases of juvenile
glaucoma that are not specifically associated with low IOP.43
It is inevitable that investigations of temporal changes in
phenotype associated with mutations in newly identified glau-
coma-causing genes will initially use retrospective data. To
minimize the potential effects of bias that stem from such
analysis, we relied on objective measurements in patients at-
tending a single tertiary referral center. This subset of patients
had detailed and accurate documentation of their clinical fea-
tures at presentation as well as a minimum of 5-year longitu-
dinal data (HRT and fields). We believe this approach offers
distinct advantages, although we accept that patients with
more complex disease may have been overrepresented. A
major limitation of this study is that our findings and conclu-
TABLE 4. Comparison between Patients with NTG, with and without the OPTN E50K Mutation, of
Presenting Optic Disc Parameters, as Measured by HRT
Group 1
(n  9)
Group 2
(n  87) P Corrected P
Disc area (mm2) 1.95  0.53 2.09  0.47 0.26
Global neuroretinal rim area (mm2) 0.50  0.28 0.89  0.31 0.001 0.02
Temporal rim area (mm2) 0.08  0.04 0.13  0.08 0.02 0.40
Superior 0.07  0.05 0.10  0.05 0.09
Inferior 0.05  0.03 0.08  0.07 0.13
Nasal rim area (mm2) 0.14  0.11 0.30  0.11 0.0004 0.008
Superior 0.08  0.04 0.14  0.06 0.006
Inferior 0.08  0.06 0.14  0.06 0.01
Data are expressed in square millimeters  SD.
TABLE 5. Comparison between Patients with NTG, with and without
the OPTN E50K Mutation, of Visual Field Progression with at Least 5
Years of Follow-up
Subgroup 1
(n  8)
Subgroup 2
(n  87) P
Patients with progressing
locations, n (%) 8 (100) 71 (81.6) 0.34
Progressing locations per
subject (n) 8.63  8.68 7.95  9.6 0.66
Mean slope of progressing
locations per year (dB/y) 2.02  0.75 1.97  1.22 0.45
Mean slope for whole
visual field per year
(dB/y) 0.57  0.36 0.43  0.66 0.15
Data are expressed as the mean  SD, unless otherwise noted.
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sions may be altered if data of other members of the pedigrees
not examined at our center, such as those previously found to
have high-tension glaucoma,18–20 were included in the analy-
sis. It remains to be seen if other specific features distinguish-
ing those with the mutation will become apparent, as may be
the case when more patients are found to carry the mutation.
We believe that this study provides important information
about the clinical behavior associated with the OPTN E50K
mutation and highlights the benefits that accrue from rigorous
phenotyping.
FIGURE 2. Visual fields of individual
4 (pedigree 1A) showing progressive
visual field damage. (A) Initial visual
fields results in the left eye and (B)
the left eye after 5 years.
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